SciBX
Science-Business eXchange

THE DISTILLERY

This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Autoimmune disease				
Autoimmune disease	Phosphoinositide 3-kinase (PI3K)	Studies in patient samples and in mice suggest that inhibiting PI3K catalytic subunit-δ could help treat T cell–mediated autoimmune diseases. In mice, the subunit-δ inhibitor IC87114 reduced antibody-induced cytokine release from T cells compared with no treatment. In samples from patients with allergic hypersensitivity or inflammatory arthritis, the inhibitor reduced allergen-driven cytokine production compared with that in controls. Next steps include identifying which autoimmune indications would be best suited for IC87114 or related inhibitors. IC87114 is a research tool owned by Calistoga Pharmaceuticals Inc. The company has two second-generation PI3K subunit-δ inhibitors—CAL-101 and CAL-263—in Phase I testing to treat hematological malignancies and inflammatory diseases, respectively. ***SciBX*** **3(8); doi:10.1038/scibx.2010.237** **Published online Feb. 25, 2010**	Patent and licensing status undisclosed	Soond, D.R. *et al. Blood*; published online Jan. 15, 2010; doi:10.1182/blood-2009-07-232330 **Contact:** Klaus Okkenhaug, The Babraham Institute, Cambridge, U.K. e-mail: klaus.okkenhaug@bbsrc.ac.uk